摘要
目的观察地西他滨联合HAG(高三尖杉酯碱+阿糖胞苷+粒细胞集落刺激因子)方案治疗复发/难治性急性髓系白血病(AML)的安全性及近、远期疗效。方法选取2011年1月至2014年3月收治的复发/难治性AML患者25例,均给予地西他滨联合HAG方案治疗,1个疗程后评价临床疗效及不良反应,并观察远期疗效。结果 25例患者中完全缓解(CR)14例、部分缓解(PR)8例、未缓解(NR)3例,染色体核型良好患者的CR率高于核型不良患者(χ2=4.80,P=0.028)。严重不良反应主要为血液学毒性(100.00%)、感染(60.00%)及胃肠道反应(8.00%)。随访截至2015年3月,5例(20.00%)存活,20例(80.00%)死亡,中位生存时间为8.48个月。结论地西他滨联合HAG方案治疗复发/难治性AML,缓解率较高,除血液毒性外的严重并发症较少。
Objective To explore the safety and short-and long-term efficacy of decitabine combined with HAG protocol（homoharringtonine＋cytarabine＋Granulocyte colony stimulating factor）in the treatment of patients with recurrent/refractory acute myeloid leukemia（AML）.Methods A total of 25recurrent/refractory AML patients from January 2011 to March 2014 were selected and all treated with decitabine combined with HAG protocol.Clinical efficacy and adverse responses were evaluated and long-term efficacy was observed after 1-cycle treatment.Results Of the 25 patients,14were complete remission（CR）,8partial remission（PR）,and 3with non-remission（NR）,the CR rate was evidently higher in patients with good karyotype than those with poor karyotype（P〈0.05）.Severe adverse responses mainly included hemorrhagic toxicity（100%）,infection（60.00%）and gastrointestinal responses（8.00%）.The follow up was ended in March 2015,and the results showed that 5（20.00%）patients survived and 20（80.00%）died,with median overall survival time being 8.48 months.Conclusion Decitabine combined with HAG protocol has higher remission rate and lower rate of severe adverse responses in patients with recurrent/refractory AML,which deserves to be widely used in clinic.
出处
《成都医学院学报》
CAS
2015年第3期310-312,共3页
Journal of Chengdu Medical College
基金
中国高校医学期刊临床专项资金(No:11520572)
关键词
地西他滨
HAG化疗方案
复发/难治性急性髓系白血病
并发症
生存期
Decitabine
HAG chemotherapeutic protocol
Recurrent/refractory acute myeloid leukemia
Complication
Survival time
